1. Pink Sheet
  2. >>Agency Leadership

Pharma Could Lose Some Commercial Info Protections As Part of FDA’s Misinformation Campaign

 
• By Sarah Karlin-Smith

Commissioner says agency’s speech restrictions to protect confidential commercial information ‘have gone too far,’ and may need to be modified to tackle spread of misinformation. Experts also said US FDA needs to do a better job conveying the uncertainty inherent in its work.

close up of person in business shoot going "shh" with finger
FDA Commissioner wants to limit some protections for confidential commercial information • Source: Shutterstock

US Food and Drug Administration Commissioner Robert Califf wants to work with Congress to fix some of the laws that restrict FDA from revealing certain confidential commercial information as part of his effort to tackle the proliferation of medical misinformation.

“We have a deficit that is a special one at the FDA, in that often we have information which by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.